Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Ventyx Biosciences Inc’s stock clocked out at $2.67, down -12.17% from its previous closing price of $3.04. In other words, the price has decreased by -$12.17 from its previous closing price. On the day, 2.26 million shares were traded. VTYX stock price reached its highest trading level at $3.035 during the session, while it also had its lowest trading level at $2.63.
Ratios:
To gain a deeper understanding of VTYX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.57 and its Current Ratio is at 19.57. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on March 12, 2024, Upgraded its rating to Overweight and sets its target price to $16 from $7 previously.
On March 12, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $12.
Wells Fargo Downgraded its Overweight to Equal Weight on November 07, 2023, whereas the target price for the stock was revised from $77 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 02 ’25 when Nuss John sold 1,887 shares for $1.07 per share. The transaction valued at 2,019 led to the insider holds 467,226 shares of the business.
Nuss John sold 21,119 shares of VTYX for $49,841 on Dec 27 ’24. The CHIEF SCIENTIFIC OFFICER now owns 464,582 shares after completing the transaction at $2.36 per share. On Dec 27 ’24, another insider, Nuss John, who serves as the Officer of the company, bought 21,119 shares for $2.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VTYX now has a Market Capitalization of 190000416 and an Enterprise Value of -28259594.
Stock Price History:
The Beta on a monthly basis for VTYX is 1.01, which has changed by 0.1508621 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, VTYX has reached a high of $3.39, while it has fallen to a 52-week low of $0.78. The 50-Day Moving Average of the stock is 12.79%, while the 200-Day Moving Average is calculated to be 36.72%.
Shares Statistics:
It appears that VTYX traded 1.67M shares on average per day over the past three months and 1010670 shares per day over the past ten days. A total of 71.16M shares are outstanding, with a floating share count of 63.06M. Insiders hold about 11.38% of the company’s shares, while institutions hold 68.58% stake in the company. Shares short for VTYX as of 1752537600 were 4965711 with a Short Ratio of 2.98, compared to 1749772800 on 6384419. Therefore, it implies a Short% of Shares Outstanding of 4965711 and a Short% of Float of 7.4099995000000005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for Ventyx Biosciences Inc (VTYX) is a result of the insights provided by 7.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.4 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$1.59 and -$2.09 for the fiscal current year, implying an average EPS of -$1.89. EPS for the following year is -$2.07, with 7.0 analysts recommending between -$1.63 and -$2.65.
